Search

everythinglearnresearchcommunity

for

Search:↓

Beard to scalp hair transplants can provide 12,000-15,000 grafts for coverage, with fast recovery time. However, beard hair may grow curly and not suitable for frontal areas.

Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.

A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user has seen no regrowth after 1 year and 2 months on finasteride, despite increasing the dose, and is inquiring about the potential of future treatments like verteporfin and gt20029 for hair regrowth.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

A user shared their positive experience with a hair transplant of 3500 grafts, showing significant improvement in appearance after 5 months. They underwent the procedure at Heva Clinic in Istanbul for $2,300 USD, which included aftercare, and attributed their hair loss to both genetics and traction alopecia from tight hairstyles.

A 19-year-old is experiencing hair thinning and recession above the temples, causing stress and consideration of starting finasteride despite financial constraints. They are unsure whether to begin treatment immediately or wait to assess the situation further.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

A 39-year-old experienced hair regrowth on his temples after switching from finasteride to topical RU58841 combined with 5% minoxidil. He also underwent stem cell treatment and noticed improvements, attributing the regrowth mainly to the change in treatment.

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

A case study that suggests verteporfin may be able to help regrow donor hairs after FUE extraction, and the potential implications of this result. Treatments discussed include Minoxidil, Finasteride, and RU58841.

A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The user is experiencing hair thinning and loss at the temples, likely due to androgenetic alopecia. Suggested treatments include finasteride and minoxidil to slow hair loss and promote regrowth, with buzzing hair short as a styling option.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A hair transplant of 3361 grafts, 11.5 months after the procedure, that resulted in a very natural looking NW1 hairline; the person who underwent this procedure has not experienced any hair loss and is expecting to have no future hairloss either.